NL-OMON55067已完成不适用
se of the Cyclops dry powder inhaler by patients with Parkinson's disease after inhalation instruction. - Use of the Cyclops by Parkinson's patients.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- Diagnosed with Parkinson's disease by a nerologist;
- •- At least 18 years of age;
- •- Signed informed consent.
排除标准
- •- Not able to understand inhalation instruction (within a maximum of 30
- •- Previously participated in the Parkinson DPI-1, DPI-2 or DPI-3 studie (prior
- •knowledge of the inhalation maneuver);
- •- Active pulmonary disease.
研究者
相似试验
进行中（未招募）
1 期
Treatment with inhalation of Ciclesonide for patients with coronavirus disease: A randomised open study.EUCTR2020-001928-34-SECapio S:t Görans Sjukhus446
进行中（未招募）
不适用
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic FibrosisEUCTR2007-001412-23-IEPharmaxis Pharmaceuticals Limited250
进行中（未招募）
1 期
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 14.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2006-004078-28-GBPharmaxis UK Limited250
进行中（未招募）
1 期
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic FibrosisEUCTR2007-001412-23-DEPharmaxis Pharmaceuticals Limited340
进行中（未招募）
不适用
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 8.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic FibrosisEUCTR2007-001412-23-GBPharmaxis Pharmaceuticals Limited340